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doi:10.1016/j.jtcvs.2008.06.035Objective: The hospital course for pediatric coarctation repair has not been described.
We had 4 aims: (1) to determine the influence of age, anatomy, and type of repair on
aortic crossclamp time, (2) to determine the impact of age or aortic crossclamp time on
postoperative morbidity, (3) to describe current antihypertensive strategies, and (4) to
describe antihypertensive medications at hospital discharge.
Methods: Data were obtained from a prospective randomized multicenter esmolol
safety and efficacy trial. The study included patients who were scheduled for a coarc-
tation repair receiving esmolol as their first-line antihypertensive medication in the
operating room (n 5 118; weight $ 2.5 kg and age , 6 years).
Results: (1) Patient age and type of coarctation did not affect the aortic crossclamp
time. (2) Younger age, but not aortic crossclamp time, was associated with a signifi-
cantly longer time to extubation and longer hospital length of stay. (3) A combination
of esmolol and sodium nitroprusside (Nipride, Roche, Basel, Switzerland) provided
excellent early blood pressure control. (4) At discharge, 64% of patients were receiv-
ing antihypertensive medications. Older patients were more likely to be discharged
with antihypertensive medication (91% of patients aged 2–6 years, P , .0002).
Conclusion: The study describes a multi-institutional approach to the repair of isolated
coarctation in infants and children. Patients repaired by end-to-end anastomosis had
shorter aortic crossclamp time, younger patients had longer hospital length of stay,
a majority of patients had sodium nitroprusside (Nipride) added to esmolol for early
blood pressure control, and older patients were more likely to be discharged with
antihypertensive medication.
S
urgical results are excellent for repair of coarctation of the aorta.1,2 Postopera-
tive hypertension in these patients is a well-recognized phenomenon, and there
are small cases series addressing the efficacy of antihypertensive medica-
tions.3-6 We utilized a multicenter esmolol safety and efficacy trial to obtain surgical
and perioperative data in infants and children aged less than 6 years undergoing repair
of coarctation of the aorta via a lateral thoracotomy.7 We had 4 specific aims from this
multi-institutional pediatric population: (1) to determine the influence of age, anat-
omy, and type of repair on aortic crossclamp time, (2) to determine the impact of
age or aortic crossclamp time on postoperative morbidity, (3) to describe current an-
tihypertensive strategies and their ability to control blood pressure in the early post-
operative period, and (4) to describe the frequency and type of antihypertensive
medications at the time of hospital discharge.
Materials and Methods
Data were obtained from a prospective randomized multicenter (Appendix A) industry-spon-
sored esmolol safety and efficacy trial and a physician investigator-initiated substudy.7 The pri-
mary study was Food and Drug Administration approved and monitored, in addition to being
approved by the individual institutions’ institutional review boards. The patient populationThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 5 1229
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DAbbreviations and Acronyms
ACEI 5 angiotensin-converting enzyme inhibitor
CI 5 confidence interval
ICU 5 intensive care unit
OR 5 odds ratio
SBP 5 systolic blood pressure
included infants and children who weighed more than 2.5 kg, were
aged less than 6 years, and were scheduled for a coarctation repair
via a lateral thoracotomy between August of 2000 and November
of 2002, whose parent or legal guardian signed informed consent.
Exclusion criteria included hypoglycemia, sensitivity to beta-
blockers, low resting heart rate, depressed ventricular function,
and abnormal screening laboratory results (Appendix B). A total
of 164 patients met inclusion criteria, and informed consent was ob-
tained. The final inclusion criterion was hypertension requiring
treatment (neonate, systolic blood pressure [SBP]$ 80 mm Hg; in-
fant, SBP$ 85 mmHg; child, SBP$ 95 mmHg) within 30 minutes
of crossclamp release. A total of 118 patients (72 %) met the SBP
criteria within 30minutes of crossclamp release and received as their
first-line antihypertensive a blinded esmolol bolus (125, 250, or 500
mg/kg) immediately followed by an esmolol infusion at the same
dose per minute (125, 250, or 500 mg/kg/min) for a minimum of
15 minutes while in the operating room. There was no placebo con-
trol. After 5 minutes, additional antihypertensive medications could
be added. After 15 minutes, changes in antihypertensive strategies
were at the discretion of the practitioners. The results of the esmolol
safety and efficacy trial are described elsewhere.7
Data presented were prospectively collected during the trial and
include patient demographics, mode of diagnosis, associated cardiac
lesions, preoperative clinical status, preoperative blood pressure
gradient, surgical data, postoperative blood pressure gradients, in-
tensive care unit (ICU) course, and use of antihypertensive agents.
Blood pressure and heart rate were recorded hourly in the ICU for
the first 12 hours and every 2 hours for the subsequent 12 hours.
Data analysis proceeded in 4 discrete steps. (1) Descriptive sta-
tistics were generated for the entire sample, focusing on preopera-
tive, operative, and postoperative factors. (2) The association
between age and crossclamp time with postoperative continuous
variables was assessed using the Spearman correlation coefficient
given the skewed nature of the distributions. For comparisons be-
tween these 2 factors and dichotomous variables, the Wilcoxon
rank-sum test was used. (3) Several separate logistic regression
models were specified and tested to estimate the relationship of
age and crossclamp time with postoperative morbidities. (4) Logis-
tic regression modeling was additionally used to estimate the
relationship among age, crossclamp time, and postoperative antihy-
pertensive treatment with discharge with antihypertensive medica-
tion. All data were analyzed using SAS 9.1 (SAS Institute, Cary,
NC).
Results
Preoperative
Patient demographics and associated anomalies are listed in
Table 1. The median age was 4.8 months (0–84 months).1230 The Journal of Thoracic and Cardiovascular Surgery c NoThree patients (2.5%) had previous cardiac surgery, all of
which were coarctation repairs. Preoperative diagnostic im-
aging included echocardiogram in 114 patients (97%) and
magnetic resonance imaging in 20 patients (17%). The duc-
tus arteriosus was patent in 30 patients (26%), but only 1 pa-
tient was receiving prostaglandins. Eight patients (7%) were
mechanically ventilated preoperatively. Preoperative labora-
tory values included amedian blood urea nitrogen of 9mg/dL
(3–21 mg/dL), creatinine of 0.4 mg/dL (0.2–1.2 mg/dL), and
hemoglobin of 12 g/dL (9–18.6g/dL).
Right arm SBP obtained in the operating room before in-
duction of anesthesia was 1196 24 mm Hg, with the associ-
ated SBP gradient to the lower extremity of 336 23 mm Hg.
Intraoperative
Operative times are shown in Table 2. Intraoperative descrip-
tion of the type of coarctation by the surgeon was discrete
(#10 mm) in 82 patients (69%) and long segment (.10
mm) in 36 patients (31%). There was no significant differ-
ence in crossclamp time between discrete (median 18 min-
utes, 8–61 minutes) and long segment (median 16 minutes,
6–30 minutes, P 5 .19) coarctation. The type of surgical re-
pair described by the surgeon and associated crossclamp
times are shown in Table 3. Aortic crossclamp times were
significantly shorter for resection with end-to-end anastomo-
sis (n 5 107, median 16 minutes, 6–31 minutes) compared
with other repairs (n 5 11, median 28 minutes, 12–61 min-
utes, P 5 .001). The length of aortic crossclamp time was
not associated with patient age (P 5 .73).
Postoperative
The postoperative course is outlined in Table 4. There was no
mortality. Twenty-five percent of patients (n 5 30) were
extubated in the operating room. Blood transfusion was ad-
ministered to 35 patients (30%). The incidence of blood
transfusion trended toward significance in younger patients
(odds ratio [OR] 0.98, 95% confidence interval [CI]
0.96–1.01, P 5 .06) and just reached significance for longer
crossclamp time (OR 1.1, 95% CI 1.0–1.14, P5 .046). Chest
radiograph revealed pleural effusions in 10 patients (8%) and
pneumothorax in 17 patients (14%). At the time of discharge,
the creatinine was 0.3 mg/dL (range 0.1–0.9 mg/dL) and
hemoglobin was 11 g/dL (range 7.0–19.8 g/dL).
Younger age was associated with a longer time to extuba-
tion (Spearman correlation coefficient20.57, P, .001) and
longer hospital length of stay (Spearman correlation coeffi-
cient20.34, P, .001). There was no significant association
between aortic crossclamp time and time to extubation or
hospital length of stay.
SBP gradient (right arm to a lower extremity) obtained 24
hours after arrival to the ICU was 76 13 mm Hg, which was
significantly lower compared with 33 6 23 mm Hg in the
operating room before induction of anesthesia (P , .001).vember 2008
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#30 d >30 d and <2 y 2–6 y Overall
N 30 52 36 118
Age, mo (median, range) 0.4 (0–1) 3.8 (1–24) 43 (27–84) 4.8 (0–84)
Weight, kg (median, range) 3.6 (2.6–4.9) 5.8 (2.8–14.6) 16.5 (10.7–26) 6.4 (2.6–26)
Male (n, %) 22 (73) 32 (62) 25 (69) 79 (67)
Congenital anomalies (n, %) 6 (20) 5 (10) 2 (6) 13 (11)
Bicuspid aortic valve (n, %) 17 (57) 31 (60) 19 (53) 67 (57)
Ventricular septal defect (n, %) 7 (23) 5 (10) 0 (0) 12 (10)CH
DAntihypertensive Therapies
After 15 minutes of esmolol in the operating room, the pro-
tocol allowed the routine use of antihypertensive medications
at the discretion of the care team. Therefore, the choice of
antihypertensive agent in the ICU was independent of the
protocol, but many centers may have chosen to continue
the blinded esmolol after reaching therapeutic goals. The fre-
quency of esmolol and sodium nitroprusside (Nipride) use
during the first 24 hours in the ICU with associated SBP is
shown by age groups in Figure 1. All patients who arrived
in the ICU were receiving esmolol, and 61 patients (59%)
were also receiving sodium nitroprusside (Nipride). The
use of a combination of esmolol and sodium nitroprusside
(Nipride) on arrival to the ICU was more common in older
children (#30 days of age 27% [8/30]; .30 days and ,2
years 54% [28/52]; 2–6 years 69% [25/36]). The need for an-
tihypertensive infusions during the first 24 postoperative
hours increased with older age. This was true for the number
of hours that patients were treated with esmolol (n 5 118;
correlation coefficient 0.38; P, .001), hours treated with so-
dium nitroprusside (Nipride) (n 5 71, correlation coefficient
0.33, P 5 .005) or hours treated with either esmolol or so-
dium nitroprusside (Nipride) (n 5 118, correlation coeffi-
cient 0.49, P , .001). During the first 24 hours in the ICU,
both infusions were gradually reduced and intermittent anti-
hypertensive medications (both intravenous and oral) were
introduced. At the end of the first 24 hours, 43 patients
(36%) were receiving esmolol and 28 patients (24%) were
receiving sodium nitroprusside (Nipride). This strategy
provided excellent blood pressure control (Figure 1). Mean
SBP during the first 24 hours was 83 6 3 mm Hg for 30
days of age or less, 103 6 5 mm Hg for more than 30 daysThe Journal of Thoraand less than 2 years, and 116 6 3 mm Hg for 2 to 6 years.
The median duration of esmolol and sodium nitroprusside
(Nipride) use after arrival in the ICU was 19.9 hours (0.3–
80.7 hours) and 18.7 hours (0.4–99.8 hours), respectively.
The median maximum dose of esmolol was 521 mg/kg/min
(125–9333 mg/kg/min), and the median maximum dose of so-
dium nitroprusside (Nipride) was 3 mg/kg/min (0.5–8 mg/kg/
min). There was a trend toward a higher maximum esmolol
dose per unit body weight (mg/kg/min) in older patients
(Spearman correlation coefficient 0.17, P 5 .07).
The initiation of intermittent antihypertensive medications
was more common in the older patients (Figure 2). These
agents were grouped into the following categories: (1) beta-
blockers (atenolol, labetolol, and propranolol); (2) angioten-
sion-converting enzyme inhibitor (enalaprilat, enalapril, and
captopril); (3) calcium channel blockers (nicardipine and
nifedipine); (4) alpha agents and vasodilators (phenoxybenz-
amine, clonidine, and hydralazine). Seventy-five patients
(64%) were discharged with antihypertensive medications
including 14 patients (12%) with a beta-blocker, 46 patients
(39%) with an angiotensin-converting enzyme inhibitor
(ACEI), and 10 patients (8.5%) with a combination of beta-
blocker and ACEI. Breakdown by age is shown in Table 5.
Older patients were more likely to be discharged with
antihypertensive medication (OR 1.1, 95% CI 1.03–1.1,
P, .0002). Neither the maximum esmolol nor sodium nitro-
prusside (Nipride) dose was associated with the need for
discharge on antihypertensive medication. However, patients
requiring both esmolol and sodium nitroprusside (Nipride)
infusions rather than a single infusion were more likely to
be discharged with antihypertensive medication (OR 6.8;
95% CI 3.0–15.7; P , .001).TABLE 2. Operative times for all patients
#30 d >30 d and <2 y 2–6 y Overall
N 30 52 36 118
Duration of anesthesia, h (median, range) 2.3 (1.6–5.8) 2.8 (1.7–5.6) 3.1 (1.6–5.8) 2.8 (1.6–5.8)
Duration of surgery,a h (median, range) 1.2 (0.8–4) 1.6 (0.8–4) 1.8 (0.8–4.5) 1.6 (0.8–4.5)
Aortic crossclamp, min (median, range) 16.0 (10–61) 16.5 (9–31) 17.0 (6–31) 16.5 (6–61)
aIncision to dressing.cic and Cardiovascular Surgery c Volume 136, Number 5 1231
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DTABLE 3. Type of repair and associated aortic crossclamp times
Type of repair #30 d >30 d and <2 y 2–6 y Overall
n 30 52 36 118
Resection, end to end
n (%) 26 (87) 49 (94) 32 (89) 107 (91)
crossclamp time, min (median, range) 16 (10–29) 16 (9–31) 17 (6–29) 16 (6–31)
Resection, end to side
n (%) 0 (0) 0 (0) 1 (3) 1 (1)
crossclamp time, min - - 28 28
Patch augmentation
n (%) 0 (0) 1 (2) 3 (8) 4 (3)
crossclamp time, min (median, range) - 12 19 (16–31) 18 (12–31)
Subclavian flap
n (%) 1 (3) 2 (4) 0 (0) 3 (3)
crossclamp time, min (median, range) 28 29 (28–31) - 28 (28–31)
Reverse subclavian flap
n (%) 3 (10) 0 (0) 0 (0) 3 (3)
crossclamp time, min (median, range) 30 (23–61) - - 30 (23–61)Discussion
Surgical outcomes for repair of coarctation of the aorta are
excellent, as recently reported for both infants2,8 and adoles-
cents.9 There is limited information on the perioperative
course and current strategies to control hypertension in the
pediatric population. The establishment of a prospective es-
molol trial provided a unique opportunity to look in a multi-
center fashion at current approaches to coarctation repair,
perioperative course, and antihypertensive therapies in chil-
dren less than 6 years of age. Four aims were addressed in
this physician investigator-initiated substudy: (1) to deter-
mine the influence of age, anatomy, and type of repair on aor-
tic crossclamp time; (2) to determine the impact of age or
aortic crossclamp time on postoperative morbidity or hospital
length of stay; (3) to describe current antihypertensive strat-
egies and their ability to control blood pressure in the early
postoperative period; and (4) to describe the frequency and
type of antihypertensive medications at the time of hospital
discharge.
Recently reported surgical approaches via a thoracotomy
vary from subclavian flap approach8 to end-to-end or ex-
tended end-to-end anastomosis.1,2,10 In this multi-institu-
tional population (n 5 107), 91% of patients had an
end-to-end anastomosis with the coarctation described by1232 The Journal of Thoracic and Cardiovascular Surgery c Nthe surgeon as discrete (,10 mm) in 69% of patients. Aortic
crossclamp time was not significantly influenced by patient
age or type of coarctation (discrete vs long-segment). The
aortic crossclamp time was significantly shorter for the
end-to-end anastomosis compared with other types of surgi-
cal repairs (P , .001).
Blood pressure was well controlled in the postoperative
period. The mean blood pressure gradient was reduced
from 346 22 mmHg to 76 14mmHg, similar to previously
reported values.10 Thirty percent of patients underwent endo-
tracheal extubation in the operating room, with a median time
to extubation of 7 hours (0–352 hours). The median time to
hospital discharge was 4 days (2–80 days). Younger age
was associated with a longer time to extubation (P , .001)
and longer hospital length of stay (P , .001). Aortic cross-
clamp time was not associated with time to extubation or hos-
pital length of stay.
Postoperative hypertension is well recognized,11-13 even
in neonates.14 This has been attributed to abnormal elastic
properties as demonstrated by echocardiography both before
and after repair in newborns15 and abnormalities in auto-
nomic function, including diminished heart rate variabil-
ity.12,14 It is uncertain whether these physiologies relate to
the observed late hypertension.16,17TABLE 4. Postoperative course
#30 d >30 d and <2 y 2–6 y Overall
n 29 52 33 114
Hours to extubationa (median, range) 21 (0–95) 5 (0–352) 1 (0–26) 7 (0–352)
Days to ICU discharge (median, range) 3 (1–11) 2 (1–16) 2 (1–4) 2 (1–16)
Days to hospital discharge (median, range) 5 (2–17) 4 (2–80) 4 (2–8) 4 (2–80)
ICU, Intensive care unit. aTime from dressing placement at end of surgery.ovember 2008
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Figure 1. Percentage of patients receiving esmo-
lol and sodium nitroprusside (Nipride, Basel,
Switzerland) infusions (left axis) during the first
24 hours after arrival in the ICU is shown with
mean SBP for the age group cohort (right axis).
A, Patients aged less than 30 days, n 5 30. B, Pa-
tients aged between 30 days and 2 years, n 5 52.
C, Patients aged between 2 and 6 years, n 5 36.
ICU, Intensive care unit; SBP, systolic blood pres-
sure.Therapies for immediate postoperative hypertension are
varied with a small case series in the literature.3-6 This patient
population provides a multi-institutional overview of the cur-
rent antihypertensive strategies used after surgical coarctation
repair in infants and children in North America, with a bias to-
ward the use of esmolol. All patients arrived in the ICU receiv-
ing esmolol, and 59% of patients were also receiving sodium
nitroprusside (Nipride). The use of antihypertensive medica-
tions increased with patient age.The Journal of ThoraAt the time of discharge (5 6 7 days), 64% of patients
were receiving antihypertension medications. Neither the
maximum esmolol nor sodium nitroprusside (Nipride)
dose was associated with the need for discharge with an-
tihypertensive medication. However, patients requiring
both esmolol and sodium nitroprusside (Nipride) infusions
rather than a single infusion were more likely to be dis-
charged with antihypertensive medication. Older patients
were more likely to require medications (P , .0002).cic and Cardiovascular Surgery c Volume 136, Number 5 1233
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Figure 2. Percentage of patients receiving inter-
mittent antihypertensive medications (left axis)
during the first 24 hours after arrival in the ICU
is shown with mean SBP for the age group cohort
(right axis). Medications were categorized as
beta-blockers (atenolol, labetolol, and proprano-
lol); angiotension-converting enzyme inhibitors
(enalaprilat, enalapril, and captopril); calcium
channel blockers (nicardipine and nifedipine);
and alpha agents and vasodilators (phenoxybenz-
amine, clonidine, hydralazine). A, Patients aged
less than 30 days, n 5 30. B, Patients aged be-
tween 30 days and 2 years, n 5 52. C, Patients
aged between 2 and 6 years, n5 36. ICU, Intensive
care unit; BB, beta-blocker; ACEI, angiotensin-
converting enzyme; CCB, calcium channel
blocker; AA, alpha agent and vasodilator; SBP,
systolic blood pressure.Only 17% of infants (5/30) aged 30 days or less were
discharged with antihypertensive medications, with all but
1 patient receiving an ACEI. However, 92% of children
(33/36) aged 2 to 6 years were discharged with antihyper-
tensive medications, with half receiving ACEI and 40%
receiving a beta-blocker or combination of beta-blocker
and ACEI.1234 The Journal of Thoracic and Cardiovascular Surgery c NoStudy Limitations
This study included only patients who gave informed consent,
met blood pressure criteria, and received intraoperative esmo-
lol. Patients described in this study were treated at institutions
that are likely biased toward the use of esmolol. The use of
blinded esmolol may likely have influenced the early choice
of antihypertensive medications.vember 2008
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DConclusions
This is the first study to describe a multi-institutional ap-
proach to surgical repair of coarctation of the aorta in pediat-
rics. There was no mortality, neurologic complications, or
clinically significant mesenteric ischemia. (1) Patient age
and type of coarctation did not affect aortic crossclamp
time, but those undergoing a resection and end-to-end anas-
tomosis (91%) had a significantly shorter crossclamp time.
(2) Younger patient age, but not aortic crossclamp time,
was associated with a significantly longer time to extubation
and longer hospital length of stay. (3) All patients arrived in
the ICU receiving esmolol, and an additional 59% of patients
were also receiving sodium nitroprusside (Nipride) (69% of
those aged 2–6 years). (4) At the time of discharge, 64% of
patients were receiving antihypertensive medications, with
angiotension-converting enzyme inhibitors and beta-
blockers most commonly used. Older patients were signifi-
cantly more likely to be discharged with antihypertensive
medication (91% of patients aged 2–6 years).
The authors thank Michelle DeSilvio, PhD, and Xuemei Zhang,
MS, for assistance with the statistical analyses.
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Appendix B. Exclusion Criteria
1. The patient has an awake resting heart rate: less than
120 bpm (neonate,#28 days), less than 90 bpm (in-
fant, .28 days and ,1 year), or less than 70 bpm
(child, $1 year and ,6 years).
2. The patient has had reactive airway disease requiring
any form of therapy within the past week or requiring
hospitalization within the past year.
3. The patient has a known sensitivity to beta-blockers
as determined by the investigator.
4. The patient is hypoglycemic (glucose , 60 mg/dL)
on their screening laboratory results.
5. The patient has participated in a randomized study or
has been exposed to an experimental drug within 28
days before enrollment in this study.
6. The patient has concomitant complex congenital
heart disease requiring cardiopulmonary bypass. He-
modynamically insignificant disease (eg, atrial septal
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defect, ventricular septal defect, or mild pulmonary
stenosis) is not reason for exclusion.
7. The patient has had an episode of shock, acidosis, or
depressed left ventricular function within 48 hours of
surgery, or is receiving dopamine (.5 mg/kg/min)
for low cardiac output.
8. The patient’s screening laboratory results include the
following: hemoglobin , 9 g/dL, platelet count ,
100,000/mL, white blood cell count, 1000/mL, cre-
atinine or blood urea nitrogen . 1.5 times the upper
limit of normal for age, alanine or aspartate amino-
transferase . 2 times the upper limit of normal for
age.
9. The patient was previously treated under this proto-
col.
10. The patient is already receiving a beta-blocker or
other long-acting antihypertensive.vember 2008
